Genomma Lab Internacional SAB De CV (LABB)

Currency in MXN
20.990
+0.050(+0.24%)
Closed·
Showing Genomma Lab Int historical data. For real-time data please try another search
Day's Range
20.57021.370
52 wk Range
15.03021.370
Key Statistics
Prev. Close
20.88
Open
20.9
Day's Range
20.57-21.37
52 wk Range
15.03-15.75
Volume
1.7M
Average Volume (3m)
4.87M
1-Year Change
37.91%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Genomma Lab Internacional SAB De CV Company Profile

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Industry
-
Sector
-
Employees
1665
Market
Mexico

Genomma Lab Internacional SAB De CV Earnings Call Summary for Q2/2025

  • Net sales up 0.5% YoY to 4,676M pesos; 5.5% growth excluding Argentina. EBITDA margin expanded 89bps to 23.8%
  • Net income down 43% due to forex losses; pro forma net income up 16.6%. Free cash flow surged 65% to 2,700M pesos
  • Projecting near-zero 2025 sales growth, single-digit Q3 contraction. Targeting 24% EBITDA margin, gradual 2026 growth
  • Planning 500M pesos CAPEX for 2025, focusing on distribution center and production line enhancements
  • CEO highlights new growth chapter, emphasizing iconic product development and speed to market as key advantages
Last Updated: 24/07/2025, 19:42
Read Full Transcript

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 0.000

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.94%
Dividend Yield
3.71%
Industry Median -
Annualised payout
0.80
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 30, 2025
EPS / Forecast
0.51 / --
Revenue / Forecast
4.41B / --
EPS Revisions
Last 90 days

LABB Income Statement

People Also Watch

197.87
AC
+0.72%
227.26
PINFRA
+1.50%
171.93
FEMSAUBD
-5.79%
43.120
BBAJIOO
-0.67%
45.400
GENTERA
+4.08%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.